Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab versus risankizumab head-to-head study in moderately to severely active Crohn's disease
2025-521590-13-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial in Crohn's disease comparing Guselkumab arm with Risankizumab arm (2 arms). Primary endpoint: Deep remission at Week 52. Planned start May 2026; status: authorised.
02
Drugs
guselkumabrisankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2025-521590-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521590-13-00.